Ftse Mib
35.390,52
-0,06%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.878,48
2,52%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Calithera Biosciences Inc (CALA) Calithera Biosciences Inc (CALA) Notizie

CALA

Calithera Biosciences (CALA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CALA
DataOraFonteTitoloSimboloCompagnia
29/06/202322:01GlobeNewswire Inc.Calithera Biosciences Announces Update on Complete Liquidation and DissolutionNASDAQ:CALACalithera Biosciences Inc
15/06/202315:14Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:CALACalithera Biosciences Inc
05/06/202323:17Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:CALACalithera Biosciences Inc
26/05/202322:29Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:CALACalithera Biosciences Inc
26/05/202313:09Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:CALACalithera Biosciences Inc
26/05/202313:09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CALACalithera Biosciences Inc
22/05/202312:01Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CALACalithera Biosciences Inc
31/03/202312:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CALACalithera Biosciences Inc
14/03/202321:16Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:CALACalithera Biosciences Inc
14/03/202321:13Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CALACalithera Biosciences Inc
14/03/202321:03Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:CALACalithera Biosciences Inc
03/03/202316:46Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:CALACalithera Biosciences Inc
14/02/202317:49Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CALACalithera Biosciences Inc
09/01/202314:00GlobeNewswire Inc.Calithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionNASDAQ:CALACalithera Biosciences Inc
15/11/202212:25TipRanksH.C. Wainwright Sticks to Its Buy Rating for Calithera Bio (CALA)NASDAQ:CALACalithera Biosciences Inc
14/11/202222:17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CALACalithera Biosciences Inc
14/11/202222:05GlobeNewswire Inc.Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNASDAQ:CALACalithera Biosciences Inc
08/11/202222:30GlobeNewswire Inc.Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022NASDAQ:CALACalithera Biosciences Inc
03/10/202215:34TipRanksCalithera Rises on Fast Track Designation for SapanisertibNASDAQ:CALACalithera Biosciences Inc
03/10/202213:56Dow Jones NewsCalithera Biosciences Gets FDA Fast Track For Lung Cancer DrugNASDAQ:CALACalithera Biosciences Inc
03/10/202213:00GlobeNewswire Inc.Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung CancerNASDAQ:CALACalithera Biosciences Inc
06/09/202222:05GlobeNewswire Inc.Calithera to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:CALACalithera Biosciences Inc
16/08/202223:23Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:CALACalithera Biosciences Inc
16/08/202212:11Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CALACalithera Biosciences Inc
15/08/202222:05GlobeNewswire Inc.Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent HighlightsNASDAQ:CALACalithera Biosciences Inc
08/08/202222:05GlobeNewswire Inc.Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022NASDAQ:CALACalithera Biosciences Inc
13/07/202222:01GlobeNewswire Inc.Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma ConferencesNASDAQ:CALACalithera Biosciences Inc
06/07/202222:01GlobeNewswire Inc.Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung CancerNASDAQ:CALACalithera Biosciences Inc
23/06/202222:05GlobeNewswire Inc.Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell LymphomaNASDAQ:CALACalithera Biosciences Inc
14/06/202218:50GlobeNewswire Inc.Calithera Biosciences Announces 1-for-20 Reverse Stock SplitNASDAQ:CALACalithera Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CALA

La tua Cronologia

USOTC
SIETY
D Ieteren (PK)
LSE
0RL0
Skeljungur
ASX
FND
Findi
BIT
UR9ZNH
UniCredit Bank
GATE
MANUSDT
Matrix AI Network
COIN
IDEXETH
IDEX Token
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network